Influx Healthtech Ltd Q1 FY27 Earnings Analysis

- Influx Healthtech targets a minimum growth of 25% to 30% in FY '27, with ambitions to surpass this range, potentially reaching 35% to 40% based on past achievements. - The company anticipates steady capacity utilization growth, with new plants expected to be operational around August, contributing approximately INR 40-50 crores in H2 FY '27. - The veterinary segment and pet care market are expected to grow significantly, with capacity increasing from 150 kg/hour to around 1000 kg/hour (an 8x increase), gradually improving margins. - Export revenues currently contribute around 15-20%, with an expected annual increase of 5-7% in export quantum. - Growth will be driven by both scaling existing clients and acquiring new clients, with the top 50-100 clients steadily expanding. - Long-term revenue targets aim for INR 450-500 crores facilitated by planned capacity expansion (2.5x current capacity).

- The company expects a minimum growth of 25% to 30% in revenue for FY '27, with potential to exceed up to 35%-40% based on past performance. - Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margins are targeted around 20% to 22%. - Profit After Tax (PAT) margins are expected to be maintained around 14%. - New facility commissioning in July-August 2026 is expected to contribute approximately INR 40-50 crores to revenue in H2 FY '27. - Gradual capacity utilization increases are anticipated; the new facility brings 2.5x installed capacity growth. - The company plans controlled, steady growth avoiding large upfront investments without secured clients. - Export revenue is expected to grow 5%-7% year-on-year, increasing its contribution beyond the current 15%-20%. - Employee cost increases reflect investments in capability building to support growth. - Overall, sustainable and steady improvement in profits and EPS aligned with capacity expansion and operational efficiencies.

- INR 13.84 crores of IPO proceeds allocated for capex utilized as of March 31, 2026. - Board approved reallocation of INR 10 crores from veterinary, home care, and cosmetic divisions to expand nutraceutical CDMO facility. - New facility (~75,000 sq. ft.) commissioning expected by July/August 2026, capacity to be 2.5x existing, targeting INR 450-500 crores revenue in a few years. - Installed a new granulation line with ~480 kg/day capacity (24,000 bottles/day). - Protein/snack bar segment growing strongly; pet food extrusion line ordered, capacity increasing from 100-150 kg/hr to 1000 kg/hr. - Beverage segment building a canning facility and carbonated line; includes Tetra pack line booked. - Investment in innovative packaging machinery (e.g., for cosmetics) imported. - No current plans for debt; growth capex funded through internal accruals and IPO proceeds. - Focus on steady, strategic capacity expansion matching customer demand.

- Currently, Influx Healthtech has sufficient funds from internal accruals and IPO proceeds to operate and expand. - No plans to raise new debt at present; the company does not intend to take on debt right now. - For the next 2-3 years, the company expects to fund growth capex primarily from internal accruals and IPO proceeds. - Management indicated no expectation of equity dilution or additional fundraising during this period. - Any additional expansion or capacity increase will be planned within existing financial resources unless future needs arise.

- The company does not have long-term contracts typical in the industry, with some clients providing projections for 3 months to 1 year (e.g., Octavius has given a 1-year plan, Novus a 3-month projection). - Existing clients are growing steadily and contributing to the order book; the top 50-100 clients remain largely the same. - The new facility, equipped with more automated lines, is expected to serve larger clients, while the current facility will cater to medium and small clients. - Capacity utilization is expected to build slowly and steadily; filling the new capacity will take time and is not expected immediately. - The company anticipates regular growth of 25-30% year-on-year, inclusive of contributions from the new facility. - The order pipeline looks healthy with new clients like Nykaa, Khandelwal Labs, and Aristo joining. - The management is confident about meeting utilization and maintaining growth momentum.